Class action lawsuits give individuals the power to match up against corporations. Class actions can be really successful if there are a large group of class members who have all sustained a relatively small loss sustained as a result of corporate criminality. The legal costs for individual members to file separately would be high. And the heavy burden on the court system would be excessive. The purpose of class actions is to give a convenient and economic solution for mass tort lawsuits.
Class action lawsuits can be brought before the United States federal courts, as governed by Rule 23 of the Federal Rules of Civil Procedure, when the suit involves class members, with common issues, across state lines. They can also be brought before the federal court if the case is connected with federal law. Class action lawsuits can also be brought before state courts. Different states may have differences in civil law and so may need individual attention or through multi-district litigation. Federal courts are more hostile to class actions than their state counterparts.
The ‘class’ consists of the group that have incurred damage or have been wronged by a businesses illegal actions or products. Examples include faulty products such as medical device defects or antitrust and securities lawsuits.
To start a class-action suit, a group must first be first certified as a ‘class’ by the court. Before certifying the court will decide if there are a large number of plaintiffs that it would otherwise burden the court to try them individually. They must also decide whether this group has common issues and that the claims of the class members must be typical of those of the putative class. The group filing the class action must be adequately representing the class. If these criteria are successfully met then the class action can be certified. Upon certification all members are notified and have the opportunity to opt out. Usually only a few members of the class need be present at the trial. Upon conclusion any award will be divided up between all members of the class. Often these types of lawsuits are settled out of court. Class actions are rarely resolved quickly and can often take years to come to a conclusion.
The class action system is not without its detractors. The system is blamed for epidemic levels of litigation abuses in state courts. The detractors claim that juries and judges are in collusion and team up to award large settlements. The end result is an increase in consumer prices.
Class actions are a thorn in the side of large corporations. The help give the little guy a much needed voice. They also help reduce pressure on the legal system. However they do have their detractors who are against the systems and suggest that lawyers are the ones who are truly winning by abusing the system.
The Food and Drug Administration approved Aprotinin in 1993, a drug marketed by Bayer as Trasylol. Until being withdrawn from the market, sales of Trasylol over the past several years had escalated to more than $600 million. Unfortunately, there are estimates that at least 10,000 patients may unnecessarily need kidney dialysis due to use of aprotinin during heart surgery. Many patients may have been injected with Trasylol to reduce blood loss during coronary artery bypass (CABG) surgery.
Patients who underwent heart surgery are largely unaware if Trasylol was used during their heart surgery. The decision to use aprotinin (Trasylol) was made by a patient's treating doctor.
A recent study, published by the New England Journal of Medicine (NEJM) (2006) reported a connection between Trasylol and increased risk of renal (kidney) failure, myocardial infarction, heart failure or stroke in patients who have had heart surgery.
Aprotinin (Trasylol) affects the way in which blood clots. Trasylol is injected into patients who are undergoing open heart surgery. Excessive bleeding, during and after heart surgery, is a serious complication. Such bleeding exposes patients to multiple risks. Aprotinin (Trasylol) is primarily used during repeat coronary artery bypass surgery to reduce the amount of bleeding. The amount of blood transfusion required is reduced by using clotting medications including Trasylol.
The NEJM study concluded that two other generic drugs were available that are safer and less expensive than Trasylol. Neither of the generic drugs (Amicar and Cyklokapron) was associated with increased risk of kidney failure, heart attack or stroke.
?The generic Amicar cost per dose = $11 ?The generic Cyklokapron cost per dose = $44 ?Trasylol cost per dose = $1300.
The Food and Drug Administration's (FDA) Cardiovascular and Renal Drug Advisory Committee met on September 21, 2006 to review recent data regarding the safety of aprotinin. On September 29, 2006, the FDA issued a public health advisory stating that it had learned Bayer failed to disclose a study that Bayer had conducted involving 67,000 patients undergoing heart surgery. Early analysis of the Bayer study suggested that Trasylol use during heart surgery was linked with risk of congestive heart failure, kidney failure, stroke and death. Bayer failed to disclose the study during the September 21, 2006 Advisory Committee meeting.
Steve94 Fields94 has sinced written about articles on various topics from Class Action, Web Development. Steve Fields is author of this article on . Find more information about. Steve94 Fields94's top article generates over 6600 views. to your Favourites.